Loading company
MDTMedtronic plc$131.6BA+Built from Cytek Biosciences, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes Cytek Biosciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$5.83+5.7%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Company outlook: revenue of $208M to $211M for Fiscal year 2026 — up 4.0% on a year earlier
Just reported
From Cytek Biosciences's results release of November 4, 2026; its quarterly report has since been filed.
Actual
$53.2M
+1.8% y/y
+11% q/q
Guided
—
No guide given
Actual
-$8.4M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade F-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 19 quarters of Cytek Biosciences, Inc.’s grade history. The other 17 go back to May 2022.
